文献速递介入腹部DSACTMR

中期肝细胞癌经动脉化疗栓塞无应答:放弃还是重复

Lack of Response to Transarterial Chemoembolization for Intermediate-Stage Hepatocellular Carcinoma: Abandon or Repeat?
PubMed 文献 · Radiology · 2021-01-19

该多中心回顾性研究纳入4154例中期肝细胞癌且Child-Pugh A级肝功能患者,评估连续经动脉化疗栓塞(cTACE)各次会话的影像学应答率及其与总生存期的相关性,并验证列线图预测应答者的效能。结论推荐在放弃cTACE前应完成三次会话;列线图可识别第三次cTACE的应答者。

要点

  • 首次cTACE应答率仅35.6%,但疾病稳定(SD)患者第二次、第三次cTACE应答率可达46.1%-58.3%,不应首次无应答即放弃。
  • 第三次cTACE后仍为SD者,后续第四至第六次cTACE应答率均低于10%;疾病进展(PD)患者再次cTACE应答率均低于5%。
  • 首次至第三次cTACE应答者5年总生存期高于无应答者(均P < .001),但第四次cTACE应答者与无应答者无显著差异(P = .21)。

核心结论

  • 推荐在放弃常规经动脉化疗栓塞(cTACE)前应完成三次会话。
  • 本研究开发的列线图可识别第三次cTACE的应答者。

研究设计与样本

  • 回顾性研究,纳入2005年1月至2012年12月三个中心连续接受cTACE的中期肝细胞癌且Child-Pugh A级肝功能患者4154例(平均年龄58岁±6,3777例男性)。
  • 主要队列3442例(平均年龄58岁±6,3129例男性),验证队列712例(平均年龄58岁±7,648例男性)。
  • 应答评估采用改良实体瘤疗效评价标准(mRECIST)。
  • 列线图基于肿瘤大小、肿瘤包膜和甲胎蛋白构建,用于预测应答者,并以敏感度和特异度进行验证。

诊断标准与关键数值

  • 主要队列首次cTACE应答率为35.6%(1227/3442),验证队列为36.7%(261/712)。
  • 主要队列中首次cTACE无应答且为SD者,第二次cTACE应答率为46.1%(719/1560);验证队列为48.4%(147/304)。
  • 主要队列中第二次cTACE无应答且为SD者,第三次cTACE应答率为58.3%(591/1014);验证队列为48.5%(98/202)。
  • 第三次、第四次、第五次cTACE无应答且为SD者,第四次、第五次、第六次cTACE应答率均低于10%;PD患者再次cTACE应答率均低于5%。
  • 列线图预测第三次cTACE应答者的敏感度和特异度:内部验证分别为75.0%和79.4%,外部验证分别为78.6%和87.0%。

临床应用与阅片要点

  • 首次cTACE无应答的SD患者可考虑重复cTACE,因第二次、第三次会话仍可获得46.1%-58.3%的应答率。
  • 第三次cTACE后仍为SD者,后续cTACE应答率低于10%,作者推荐在放弃cTACE前完成三次会话。
  • PD患者再次cTACE应答率低于5%,可据此评估是否继续cTACE。
  • 列线图可用于预测第三次cTACE的应答者,辅助筛选可能获益的患者。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

Background Transarterial chemoembolization (TACE) is the standard treatment for intermediate-stage hepatocellular carcinoma (HCC). It is unknown whether conventional TACE (cTACE) should be continued or abandoned after initial nonresponse for intermediate-stage HCC. The optimal number of sessions before abandoning cTACE remains debated. Purpose To define the number of sessions that patients who do not respond to treatment (hereafter, nonresponders, with stable disease [SD] or progressive disease [PD]) should undergo before abandoning cTACE. Materials and Methods Patients with intermediate-stage HCC and Child-Pugh A liver function who underwent consecutive cTACE sessions between January 2005 and December 2012 were retrospectively included from three centers. Radiologic response rate to each session and its correlation with overall survival were evaluated. Response was assessed by modified Response Evaluation Criteria in Solid Tumors. A nomogram constructed by using tumor size, tumor capsule, and α-fetoprotein to predict patients who responded to treatment (hereafter, responders) was validated with sensitivity and specificity. Results This study evaluated 4154 patients (mean age, 58 years ± 6 [standard deviation]; 3777 men; primary cohort, 3442 patients [mean age, 58 years ± 6; 3129 men]; validation cohort, 712 patients [mean age, 58 years ± 7; 648 men]). Response rate to first cTACE was 35.6% (1227 of 3442, primary cohort) and 36.7% (261 of 712, validation cohort). For patients with SD who were nonresponders to first cTACE, the response rates after second cTACE were 46.1% (719 of 1560) and 48.4% (147 of 304); for patients with SD who were nonresponders to the second cTACE session, the response rates after the third cTACE session were 58.3% (591 of 1014) and 48.5% (98 of 202). For patients with SD who were nonresponders to third, fourth, and fifth cTACE sessions, response rates after fourth, fifth, and sixth cTACE sessions were less than 10%. All response rates in patients with PD who were nonresponders to the next cTACE were less than 5%. Responders to first, second, and third cTACE had higher 5-year overall survival than nonresponders (all P < .001) but responders to the fourth cTACE did not (P = .21). The sensitivity and specificity of a nomogram predicted responders to third cTACE: 75.0% and 79.4% (internal validation) and 78.6% and 87.0% (external validation), respectively. Conclusion Three sessions were recommended before abandoning conventional transarterial embolization (cTACE) for intermediate-stage hepatocellular carcinoma. The nomogram developed in this study identified responders to third cTACE. © RSNA, 2021 Online supplemental material is available for this article. See also the editorial by Georgiades in this issue.

来源:Radiology,查看原文。版权归原作者所有。

引用

  1. Chen S, Peng Z, Zhang Y, et al. Lack of Response to Transarterial Chemoembolization for Intermediate-Stage Hepatocellular Carcinoma: Abandon or Repeat? Radiology. 2021. PMID: 33464183. doi:10.1148/radiol.2021202289

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。